Trip.com stock sinks nearly 18% after China antitrust probe notice — what investors watch now

Trip.com stock sinks nearly 18% after China antitrust probe notice — what investors watch now

New York, January 14, 2026, 15:03 (EST) — Regular session

Shares of Trip.com Group Limited’s U.S.-listed depositary receipts dropped 17.7% to $62.26 in Wednesday afternoon trading. The company revealed it is under investigation by China’s market regulator. Trip.com (Nasdaq: TCOM; HKEX: 9961) said it will cooperate fully and assured that its operations continue as usual. (PR Newswire)

This shift highlights just how fast regulatory concerns can upend valuations for China-linked platform firms, despite months of upbeat sentiment on travel demand.

China’s State Administration for Market Regulation (SAMR) has launched an investigation into Trip.com, suspecting it of abusing its dominant market position. The agency opened the case following initial reviews but didn’t specify the allegations. Under China’s anti-monopoly law, companies can be slapped with fines ranging from 1% to 10% of their previous year’s annual sales. Back in December, a Yunnan homestay industry group claimed to have collected complaints about coercive contract terms, commission hikes, and traffic blocking by several platforms, Trip.com included. The company recently reported a 16% jump in third-quarter net revenue. For context, China’s earlier antitrust crackdown saw Alibaba hit with a record 18 billion yuan fine in 2021. (Reuters)

In Hong Kong, shares dropped roughly 6.5% earlier, according to TipRanks. JPMorgan held its rating but warned the “overhang” — uncertainty surrounding the stock — might persist for months while investors await a penalty ruling. (TipRanks)

The Trip.com situation reflects a wider trend, noted Li Chengdong, founder and chief analyst at Beijing’s Dolphin consultancy. “Antitrust enforcement could become normalised,” he said. (South China Morning Post)

Trip.com fell amid a sluggish day for travel stocks but lagged behind its rivals. Booking Holdings slipped 3.7%, Expedia dropped 5.3%, and Airbnb tumbled 6.7%. The S&P 500 ETF (SPY) lost 0.8%, while the Nasdaq-tracking QQQ dipped 1.5%. The China internet ETF (KWEB) held steady, and the iShares China Large-Cap ETF (FXI) edged down roughly 0.6%.

Investors are now focused on which practices are being scrutinized and if any fixes extend beyond just a fine. Signs that pricing, commissions, or supplier ranking policies are involved could hit margins.

Probes often stretch out, and a hefty fine or forced tweaks to partner agreements could hit right as the company enters a key travel season. If demand dips then, coping with those blows would get tougher.

Next up: watch for any fresh statements from SAMR or Trip.com before the Lunar New Year holiday on Feb. 17, a period when travel usually spikes across China. Booking and listing activity heading into the break could offer an early signal on whether the investigation is shifting behavior on either side of the platform. (Timeanddate)

Stock Market Today

  • Why Nvidia stock stalls as AI optimism wavers; catalysts and deals eyed
    January 14, 2026, 4:17 PM EST. Nvidia has lagged the market rally, though the stock is up about 38% in the last 12 months. It slipped 2.6% year-to-date and about 1% in the last three months, underperforming the S&P 500 as investors weigh AI profitability. Demand for Nvidia's rapidly expanding product pipeline remains robust, according to analysts, even as sentiment around AI monetization weighs on the name. Veteran tech analyst Paul Meeks says the pullback reflects macro concerns rather than valuation, and he sees upside toward $250 within two years. Potential catalysts include deal announcements with major customers such as General Motors or Johnson & Johnson, plus fourth-quarter guidance and 2026 AI capex from hyperscalers. Wolfe Research's Chris Caso remains constructive, highlighting improvements in the Vera Rubin platform.
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom
Previous Story

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Reddit stock slips as insider sales surface, even after Evercore starts RDDT with $320 target
Next Story

Reddit stock slips as insider sales surface, even after Evercore starts RDDT with $320 target

Go toTop